Cardiol Therapeutics (TSE:CRDL) Announces Earnings Results

Cardiol Therapeutics (TSE:CRDL) announced its earnings results on Tuesday. The company reported C($0.07) EPS for the quarter, FiscalAI reports.

Cardiol Therapeutics Stock Up 10.5%

TSE:CRDL traded up C$0.18 during trading hours on Tuesday, hitting C$1.89. 285,203 shares of the stock traded hands, compared to its average volume of 105,028. The firm has a 50 day moving average price of C$1.41 and a 200 day moving average price of C$1.44. The firm has a market cap of C$211.08 million, a price-to-earnings ratio of -4.61 and a beta of 0.94. Cardiol Therapeutics has a fifty-two week low of C$1.09 and a fifty-two week high of C$2.17. The company has a current ratio of 3.89, a quick ratio of 6.84 and a debt-to-equity ratio of 1.40.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.